Loading…

Increased Antiviral Medication Sales Before the 2005–06 Influenza Season — New York City

Oseltamivir, zanamivir, rimantadine, and amantadine are antiviral medications approved for the treatment and/or prophylaxis of influenza A and/or B, although high levels of resistance among circulating strains of influenza A led CDC to issue interim recommendations in January 2005, advising that ama...

Full description

Saved in:
Bibliographic Details
Published in:MMWR. Morbidity and mortality weekly report 2006-03, Vol.55 (10), p.277-279
Main Authors: Miller, J, Schmit, K, Duncan, P, Waters, C, Johnson, G, Chang, H, Wallace, B, Kacica, M, Smith, P, Das, D, Harper, S, Heffernan, R, Olson, D, Nivin, B, Weiss, D
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 279
container_issue 10
container_start_page 277
container_title MMWR. Morbidity and mortality weekly report
container_volume 55
creator Miller, J
Schmit, K
Duncan, P
Waters, C
Johnson, G
Chang, H
Wallace, B
Kacica, M
Smith, P
Das, D
Harper, S
Heffernan, R
Olson, D
Nivin, B
Weiss, D
description Oseltamivir, zanamivir, rimantadine, and amantadine are antiviral medications approved for the treatment and/or prophylaxis of influenza A and/or B, although high levels of resistance among circulating strains of influenza A led CDC to issue interim recommendations in January 2005, advising that amantadine and rimantadine not be used for the treatment or prevention of influenza A during the 2005-06 influenza season. As part of syndromic surveillance, the New York State Department of Health (NYSDOH) monitors sales of antiviral influenza medications paid for by the Medicaid system, and the New York City Department of Health and Mental Hygiene (NYCDOHMH) monitors sales of antiviral influenza medications by a retail pharmacy chain. Syndromic data are used in combination with data provided by laboratories, health-care facilities, and health-care providers to monitor influenza activity. In October 2005, a spike in antiviral medication sales was noted. The spike did not coincide with other markers of influenza activity but did coincide with the beginning of media coverage of avian influenza A (H5N1) and the potential for an influenza pandemic. Tracking prescription medication sales can detect spikes for which no immediate indication exists. Such syndromic data might be used to guide issuance of public health recommendations regarding the limited availability of certain medications and the inadvisability of personal stockpiling.
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_67756339</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A144294386</galeid><jstor_id>23316882</jstor_id><sourcerecordid>A144294386</sourcerecordid><originalsourceid>FETCH-LOGICAL-g254t-224fe362a56e436cb4dba6197eea15ba3d477ccb1b9d16cddd84d08051c71b823</originalsourceid><addsrcrecordid>eNptkc1O3DAQxyNEBcuWR6DyiVtQ_JnkuKz4WIm2B0BqpUqRY092DVkbbAcEJ96BPuE-Sb1aWhWJmcNIM7_5az62shHmjOeVwD-2s1GBWZ0TXPPdbC-Em2JttNjJdrHgjFYVGWW_ZlZ5kAE0mthoHoyXPfoK2igZjbPoUvYQ0DF0zgOKC0CkKPjq5bUQaGa7fgD7LNFlEkjs6uU3-gaP6Kfzt2hq4tPn7FMn-wD7b3GcXZ-eXE3P84vvZ7Pp5CKfE85iTgjrgAoiuQBGhWqZbqXAdQkgMW8l1awslWpxW2sslNa6YrqoCo5ViduK0HF2uNG98-5-gBCbpQkK-l5acENoRFlyQWmdwHwDztNajbGdi16qOVhIazsLnUnpCWaM1Ok-IvFHH_DJNSyN-rDh8L-GBcg-LoLrh_Utw3vwy9vIQ7sE3dx5s5T-qfn7mQQcbICbEJ3_VyeUYrGu_wHdPJOX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67756339</pqid></control><display><type>article</type><title>Increased Antiviral Medication Sales Before the 2005–06 Influenza Season — New York City</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>ProQuest Social Science Premium Collection</source><creator>Miller, J ; Schmit, K ; Duncan, P ; Waters, C ; Johnson, G ; Chang, H ; Wallace, B ; Kacica, M ; Smith, P ; Das, D ; Harper, S ; Heffernan, R ; Olson, D ; Nivin, B ; Weiss, D</creator><creatorcontrib>Miller, J ; Schmit, K ; Duncan, P ; Waters, C ; Johnson, G ; Chang, H ; Wallace, B ; Kacica, M ; Smith, P ; Das, D ; Harper, S ; Heffernan, R ; Olson, D ; Nivin, B ; Weiss, D ; Centers for Disease Control and Prevention (CDC)</creatorcontrib><description>Oseltamivir, zanamivir, rimantadine, and amantadine are antiviral medications approved for the treatment and/or prophylaxis of influenza A and/or B, although high levels of resistance among circulating strains of influenza A led CDC to issue interim recommendations in January 2005, advising that amantadine and rimantadine not be used for the treatment or prevention of influenza A during the 2005-06 influenza season. As part of syndromic surveillance, the New York State Department of Health (NYSDOH) monitors sales of antiviral influenza medications paid for by the Medicaid system, and the New York City Department of Health and Mental Hygiene (NYCDOHMH) monitors sales of antiviral influenza medications by a retail pharmacy chain. Syndromic data are used in combination with data provided by laboratories, health-care facilities, and health-care providers to monitor influenza activity. In October 2005, a spike in antiviral medication sales was noted. The spike did not coincide with other markers of influenza activity but did coincide with the beginning of media coverage of avian influenza A (H5N1) and the potential for an influenza pandemic. Tracking prescription medication sales can detect spikes for which no immediate indication exists. Such syndromic data might be used to guide issuance of public health recommendations regarding the limited availability of certain medications and the inadvisability of personal stockpiling.</description><identifier>ISSN: 0149-2195</identifier><identifier>EISSN: 1545-861X</identifier><identifier>PMID: 16543882</identifier><language>eng</language><publisher>United States: Centers for Disease Control and Prevention</publisher><subject>Anti-infective agents ; Antiviral Agents - supply &amp; distribution ; Antiviral Agents - therapeutic use ; Antivirals ; Commerce ; Drug prescriptions ; Drug Utilization - statistics &amp; numerical data ; Health aspects ; Humans ; Influenza ; Influenza A virus ; Influenza, Human - epidemiology ; Influenza, Human - prevention &amp; control ; Medicaid ; Medications ; New York City - epidemiology ; Pharmacies ; Population Surveillance ; Public health ; Recommendations ; Seasons ; Specimens ; Statistics ; Surveillance</subject><ispartof>MMWR. Morbidity and mortality weekly report, 2006-03, Vol.55 (10), p.277-279</ispartof><rights>COPYRIGHT 2006 U.S. Government Printing Office</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/23316882$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/23316882$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,33589,58213,58446</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16543882$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miller, J</creatorcontrib><creatorcontrib>Schmit, K</creatorcontrib><creatorcontrib>Duncan, P</creatorcontrib><creatorcontrib>Waters, C</creatorcontrib><creatorcontrib>Johnson, G</creatorcontrib><creatorcontrib>Chang, H</creatorcontrib><creatorcontrib>Wallace, B</creatorcontrib><creatorcontrib>Kacica, M</creatorcontrib><creatorcontrib>Smith, P</creatorcontrib><creatorcontrib>Das, D</creatorcontrib><creatorcontrib>Harper, S</creatorcontrib><creatorcontrib>Heffernan, R</creatorcontrib><creatorcontrib>Olson, D</creatorcontrib><creatorcontrib>Nivin, B</creatorcontrib><creatorcontrib>Weiss, D</creatorcontrib><creatorcontrib>Centers for Disease Control and Prevention (CDC)</creatorcontrib><title>Increased Antiviral Medication Sales Before the 2005–06 Influenza Season — New York City</title><title>MMWR. Morbidity and mortality weekly report</title><addtitle>MMWR Morb Mortal Wkly Rep</addtitle><description>Oseltamivir, zanamivir, rimantadine, and amantadine are antiviral medications approved for the treatment and/or prophylaxis of influenza A and/or B, although high levels of resistance among circulating strains of influenza A led CDC to issue interim recommendations in January 2005, advising that amantadine and rimantadine not be used for the treatment or prevention of influenza A during the 2005-06 influenza season. As part of syndromic surveillance, the New York State Department of Health (NYSDOH) monitors sales of antiviral influenza medications paid for by the Medicaid system, and the New York City Department of Health and Mental Hygiene (NYCDOHMH) monitors sales of antiviral influenza medications by a retail pharmacy chain. Syndromic data are used in combination with data provided by laboratories, health-care facilities, and health-care providers to monitor influenza activity. In October 2005, a spike in antiviral medication sales was noted. The spike did not coincide with other markers of influenza activity but did coincide with the beginning of media coverage of avian influenza A (H5N1) and the potential for an influenza pandemic. Tracking prescription medication sales can detect spikes for which no immediate indication exists. Such syndromic data might be used to guide issuance of public health recommendations regarding the limited availability of certain medications and the inadvisability of personal stockpiling.</description><subject>Anti-infective agents</subject><subject>Antiviral Agents - supply &amp; distribution</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antivirals</subject><subject>Commerce</subject><subject>Drug prescriptions</subject><subject>Drug Utilization - statistics &amp; numerical data</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Influenza</subject><subject>Influenza A virus</subject><subject>Influenza, Human - epidemiology</subject><subject>Influenza, Human - prevention &amp; control</subject><subject>Medicaid</subject><subject>Medications</subject><subject>New York City - epidemiology</subject><subject>Pharmacies</subject><subject>Population Surveillance</subject><subject>Public health</subject><subject>Recommendations</subject><subject>Seasons</subject><subject>Specimens</subject><subject>Statistics</subject><subject>Surveillance</subject><issn>0149-2195</issn><issn>1545-861X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNptkc1O3DAQxyNEBcuWR6DyiVtQ_JnkuKz4WIm2B0BqpUqRY092DVkbbAcEJ96BPuE-Sb1aWhWJmcNIM7_5az62shHmjOeVwD-2s1GBWZ0TXPPdbC-Em2JttNjJdrHgjFYVGWW_ZlZ5kAE0mthoHoyXPfoK2igZjbPoUvYQ0DF0zgOKC0CkKPjq5bUQaGa7fgD7LNFlEkjs6uU3-gaP6Kfzt2hq4tPn7FMn-wD7b3GcXZ-eXE3P84vvZ7Pp5CKfE85iTgjrgAoiuQBGhWqZbqXAdQkgMW8l1awslWpxW2sslNa6YrqoCo5ViduK0HF2uNG98-5-gBCbpQkK-l5acENoRFlyQWmdwHwDztNajbGdi16qOVhIazsLnUnpCWaM1Ok-IvFHH_DJNSyN-rDh8L-GBcg-LoLrh_Utw3vwy9vIQ7sE3dx5s5T-qfn7mQQcbICbEJ3_VyeUYrGu_wHdPJOX</recordid><startdate>20060317</startdate><enddate>20060317</enddate><creator>Miller, J</creator><creator>Schmit, K</creator><creator>Duncan, P</creator><creator>Waters, C</creator><creator>Johnson, G</creator><creator>Chang, H</creator><creator>Wallace, B</creator><creator>Kacica, M</creator><creator>Smith, P</creator><creator>Das, D</creator><creator>Harper, S</creator><creator>Heffernan, R</creator><creator>Olson, D</creator><creator>Nivin, B</creator><creator>Weiss, D</creator><general>Centers for Disease Control and Prevention</general><general>U.S. Government Printing Office</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20060317</creationdate><title>Increased Antiviral Medication Sales Before the 2005–06 Influenza Season — New York City</title><author>Miller, J ; Schmit, K ; Duncan, P ; Waters, C ; Johnson, G ; Chang, H ; Wallace, B ; Kacica, M ; Smith, P ; Das, D ; Harper, S ; Heffernan, R ; Olson, D ; Nivin, B ; Weiss, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g254t-224fe362a56e436cb4dba6197eea15ba3d477ccb1b9d16cddd84d08051c71b823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Anti-infective agents</topic><topic>Antiviral Agents - supply &amp; distribution</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antivirals</topic><topic>Commerce</topic><topic>Drug prescriptions</topic><topic>Drug Utilization - statistics &amp; numerical data</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Influenza</topic><topic>Influenza A virus</topic><topic>Influenza, Human - epidemiology</topic><topic>Influenza, Human - prevention &amp; control</topic><topic>Medicaid</topic><topic>Medications</topic><topic>New York City - epidemiology</topic><topic>Pharmacies</topic><topic>Population Surveillance</topic><topic>Public health</topic><topic>Recommendations</topic><topic>Seasons</topic><topic>Specimens</topic><topic>Statistics</topic><topic>Surveillance</topic><toplevel>online_resources</toplevel><creatorcontrib>Miller, J</creatorcontrib><creatorcontrib>Schmit, K</creatorcontrib><creatorcontrib>Duncan, P</creatorcontrib><creatorcontrib>Waters, C</creatorcontrib><creatorcontrib>Johnson, G</creatorcontrib><creatorcontrib>Chang, H</creatorcontrib><creatorcontrib>Wallace, B</creatorcontrib><creatorcontrib>Kacica, M</creatorcontrib><creatorcontrib>Smith, P</creatorcontrib><creatorcontrib>Das, D</creatorcontrib><creatorcontrib>Harper, S</creatorcontrib><creatorcontrib>Heffernan, R</creatorcontrib><creatorcontrib>Olson, D</creatorcontrib><creatorcontrib>Nivin, B</creatorcontrib><creatorcontrib>Weiss, D</creatorcontrib><creatorcontrib>Centers for Disease Control and Prevention (CDC)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>MMWR. Morbidity and mortality weekly report</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miller, J</au><au>Schmit, K</au><au>Duncan, P</au><au>Waters, C</au><au>Johnson, G</au><au>Chang, H</au><au>Wallace, B</au><au>Kacica, M</au><au>Smith, P</au><au>Das, D</au><au>Harper, S</au><au>Heffernan, R</au><au>Olson, D</au><au>Nivin, B</au><au>Weiss, D</au><aucorp>Centers for Disease Control and Prevention (CDC)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased Antiviral Medication Sales Before the 2005–06 Influenza Season — New York City</atitle><jtitle>MMWR. Morbidity and mortality weekly report</jtitle><addtitle>MMWR Morb Mortal Wkly Rep</addtitle><date>2006-03-17</date><risdate>2006</risdate><volume>55</volume><issue>10</issue><spage>277</spage><epage>279</epage><pages>277-279</pages><issn>0149-2195</issn><eissn>1545-861X</eissn><abstract>Oseltamivir, zanamivir, rimantadine, and amantadine are antiviral medications approved for the treatment and/or prophylaxis of influenza A and/or B, although high levels of resistance among circulating strains of influenza A led CDC to issue interim recommendations in January 2005, advising that amantadine and rimantadine not be used for the treatment or prevention of influenza A during the 2005-06 influenza season. As part of syndromic surveillance, the New York State Department of Health (NYSDOH) monitors sales of antiviral influenza medications paid for by the Medicaid system, and the New York City Department of Health and Mental Hygiene (NYCDOHMH) monitors sales of antiviral influenza medications by a retail pharmacy chain. Syndromic data are used in combination with data provided by laboratories, health-care facilities, and health-care providers to monitor influenza activity. In October 2005, a spike in antiviral medication sales was noted. The spike did not coincide with other markers of influenza activity but did coincide with the beginning of media coverage of avian influenza A (H5N1) and the potential for an influenza pandemic. Tracking prescription medication sales can detect spikes for which no immediate indication exists. Such syndromic data might be used to guide issuance of public health recommendations regarding the limited availability of certain medications and the inadvisability of personal stockpiling.</abstract><cop>United States</cop><pub>Centers for Disease Control and Prevention</pub><pmid>16543882</pmid><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0149-2195
ispartof MMWR. Morbidity and mortality weekly report, 2006-03, Vol.55 (10), p.277-279
issn 0149-2195
1545-861X
language eng
recordid cdi_proquest_miscellaneous_67756339
source JSTOR Archival Journals and Primary Sources Collection; ProQuest Social Science Premium Collection
subjects Anti-infective agents
Antiviral Agents - supply & distribution
Antiviral Agents - therapeutic use
Antivirals
Commerce
Drug prescriptions
Drug Utilization - statistics & numerical data
Health aspects
Humans
Influenza
Influenza A virus
Influenza, Human - epidemiology
Influenza, Human - prevention & control
Medicaid
Medications
New York City - epidemiology
Pharmacies
Population Surveillance
Public health
Recommendations
Seasons
Specimens
Statistics
Surveillance
title Increased Antiviral Medication Sales Before the 2005–06 Influenza Season — New York City
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T10%3A00%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20Antiviral%20Medication%20Sales%20Before%20the%202005%E2%80%9306%20Influenza%20Season%20%E2%80%94%20New%20York%20City&rft.jtitle=MMWR.%20Morbidity%20and%20mortality%20weekly%20report&rft.au=Miller,%20J&rft.aucorp=Centers%20for%20Disease%20Control%20and%20Prevention%20(CDC)&rft.date=2006-03-17&rft.volume=55&rft.issue=10&rft.spage=277&rft.epage=279&rft.pages=277-279&rft.issn=0149-2195&rft.eissn=1545-861X&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA144294386%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-g254t-224fe362a56e436cb4dba6197eea15ba3d477ccb1b9d16cddd84d08051c71b823%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67756339&rft_id=info:pmid/16543882&rft_galeid=A144294386&rft_jstor_id=23316882&rfr_iscdi=true